Birthright citizenship dispute at the Supreme Court has broad implications for Trump's agendaNew Foto - Birthright citizenship dispute at the Supreme Court has broad implications for Trump's agenda

WASHINGTON — The Supreme Court could give a major boost to the Trump administration's muscular use of executive power when it hears arguments Thursday over his plan to end birthright citizenship. The court is not actually using a trio of cases before it to give the final word on whether Trump can radically reinterpret the long-understood meaning of the Constitution's 14th Amendment. Instead, it will focus on the power of judges to block presidential policies across the country. Trump's plan to limit birthright citizenship to people born to at least one parent who is a U.S. citizen or permanent legal resident is likely to ultimately be struck down,most legal experts say. The 14th Amendment states: "All persons born or naturalized in the United States, and subject to the jurisdiction thereof, are citizens of the United States." But for now, the Supreme Court — which has a 6-3 conservative majority, including three Trump appointees — is focusing only on the question of whether lower-court judges had the authority to block the policy nationwide, as three did in different cases. The administration and its allies have for months raged at judges for issuing "universal injunctions" that have stymied Trump's aggressive use of executive power. Republicans in Congress quickly introduced legislation on the issue, whichwas approvedby the House of Representatives last month. It has not come up for a vote in the Senate. "Universal injunctions issued by district court judges ... continue to fundamentally thwart the president's ability to implement his agenda," a Justice Department official said Tuesday in a call with reporters. The administration sees such rulings as a "direct attack" on presidential power, the official added. There have been 39 such rulings so far during Trump's second term, according to the Justice Department. Injunctions have, among other things, blocked some federal funding cuts and federal employee firings instituted under the direction of Elon Musk's Department of Government Efficiency. In other litigation, two courts blocked Trump's transgender military ban nationwide before the Supreme Courtintervenedand allowed it to go into effect. The administration is asking the court to limit the scope of the birthright citizenship injunctions so that they apply only to individual people, organizations that sued or potentially the 22 states that challenged Trump's executive order. If the Supreme Court agrees, the Trump administration may be able to implement the policy in part, even as litigation continues and more people sue to obtain rulings that apply to them. "The birthright citizenship case is a good example of what is at stake," Colorado Attorney General Phil Weiser, a Democrat who joined one of the legal challenges, said in an interview. "If you literally have to bring separate cases for every single plaintiff, you are limiting the ability of courts to declare what the law is and protect people." He said the Trump administration is seeking to "limit judicial oversight over illegal action." Broad injunctions against presidential policies are a relatively new phenomenon but have not uniquely targeted Trump. The Obama and Biden administration chafed at similar rulings on issues such as immigration policy. ACongressional Research Service reportfound that there were 28 universal injunctions in the four years of the Biden administration and 86 during the first Trump administration, although it conceded a precise number is difficult to pin down. Previously, the Justice Department reported there were 19 such injunctions during the eight-year Obama administration, the report said. Although all recent presidents have sought to use executive power to circumvent a deadlocked Congress, Trump has been particularly expansive, especially in his second term, which helps explain the high number of injunctions against his administration. Five of the six members of the Supreme Court's conservative majority have, in various cases, raised concerns about universal injunctions and suggested that they should be curbed in certain circumstances. In a2024 opinion, conservative Justice Neil Gorsuch wrote that it was a "question of great significance that has been in need of the court's attention of some time." The key issue is whether judges have the authority to issue injunctions that sweep beyond the parties directly involved in the litigation. Samuel Bray, a professor at Notre Dame Law School, has argued against nationwide injunctions and is cited in the birthright citizenship court papers. He said in an interview that a universal injunction "circumvents normal legal process," in part because it does not allow for a legal issue to be fully fleshed out by different courts before it reaches the Supreme Court, which has the final word. "A court doesn't decide the question for the country just because they are the first," he added. If the Supreme Court does curb universal injunctions, it would encourage lawyers to bring class-action lawsuits instead, which could include all people affected by a specific policy and would be the appropriate mechanism, Bray said. Such suits could be brought by people who would be directly affected by the birthright citizenship order, such as pregnant women who entered the country illegally. In recent years, presidential administrations of both parties have rushed to the Supreme Court when a policy is blocked nationwide, leading to the justices intervening sooner than they otherwise would, sometimes without full briefing. That practice could change somewhat if the court limits the scope of injunctions. GianCarlo Canaparo, a legal fellow at the Trump-allied Heritage Foundation, predicted that curtailing the power of judges to issue universal injunctions would lower the stakes in certain cases. But, he added, "the litigation will still proceed with as much vigor and speed."

Birthright citizenship dispute at the Supreme Court has broad implications for Trump's agenda

Birthright citizenship dispute at the Supreme Court has broad implications for Trump's agenda WASHINGTON — The Supreme Court could give ...
Trump's trade war wins so far: More talk, uncertainty and deadlinesNew Foto - Trump's trade war wins so far: More talk, uncertainty and deadlines

More than a month after PresidentDonald Trump's tariff-focused "Liberation Day," just about all America has won is more deadlines and assurances of ongoing talks. WithChina, the U.S. has secured no major changes other thanoffsetting step-downsof recent import duties and import restrictions. And anaccord with the U.K., announced last Wednesday, offered little beyond improved access for U.S. meats and ethanol. The White House has said both agreements are starting points. While it's been enough to soothe international markets andrestore U.S. stock gains, the Trump administration has little to show in the way of concessions gained from the agreements. The U.K. agreement saw British businesses win clear concessions from the Trump administration, including lower U.S. trade barriers for its vehicles, steel and aluminum products. Less clear were the immediate gains for America. Though the pact touted improved access to U.K. markets for American meat producers,methods of meat preparation common in the U.S. are banned in the U.K.— a stance it is not expected to change. Meanwhile, representatives for American auto firms — which have alreadystruggled to navigate Trump's tariffs— issued a rare statement blasting the deal. "We are disappointed that the administration prioritized the U.K. ahead of our North American partners," Matt Blunt, president of the American Automotive Policy Council, said in a statement. But the deal announcements kept coming. Days later, representatives from the U.S. and China said they had agreed to temporarily lower reciprocal tariffs, which had reached more than 120%. Again, the announcement was met with questions about its success. Capital Economics, a Wall Street consultancy, called it "another substantial retreat from the Trump administration's aggressive stance." The firm said in a note to clients that the deal does not include "any commitments by China on exchange rate policy or the bilateral trade imbalance." "They stood their ground," Marcus Noland, an economist and senior fellow at the Peterson Institute for International Economics, said of China. "They faced the bully and the United States backed down without any major concession." Chinahas hailedthe outcome of its negotiations, saying its resistance to Trump's tariffs had been "very effective." "The retaliatory measures have indeed had a significant impact on the U.S. side, which is why the U.S. government lowered the tariffs to the baseline level after the talks," asocial mediaaccount linked to China's national broadcaster CCTV said Monday. In a statement, a White House representative continued to hail the agreements while hinting that more progress was forthcoming. White House officials have also noted that recent economic data, like jobs and inflation, has continued to be solid. "Thanks to President Trump's tariffs and dealmaking, the U.K. has opened up billions in export opportunities for American ranchers and farmers while China has agreed to expand market access for American companies," White House spokesperson Kush Desai said. "And this is just the beginning, with many more deals and opportunities for American workers and farmers ahead." Trump has also touted the ability of tariffs to raise revenues. In April, the first full month that most of Trump's tariffs would have gone into effect, tariff income topped $16 billion,CNBC reported. While that is a record, it hardly dents the federal deficit, which totaled $1.05 trillion, 13% higher than a year ago. Net interest alone cost $38 billion on the month and is now $579 billion for the current fiscal year. At the same time, the tariffs that Trump has argued would generate significant revenues and encourage U.S. companies to bring production back to the U.S. are now being scaled back. Analysts warn that even as markets have responded positively to the overall set of developments, they risk being lulled into complacency given ongoing tensions and stumbling blocks. As part of the U.K. agreement, the U.S. insisted that it reduce its reliance on Chinese supply chains —something China denounced in a Tuesday Financial Times report. "I think we're in for a lot more turbulence and a lot more back-and-forth than the markets seem to grasp," Noland said.

Trump's trade war wins so far: More talk, uncertainty and deadlines

Trump's trade war wins so far: More talk, uncertainty and deadlines More than a month after PresidentDonald Trump's tariff-focused ...
Noem's claim that Afghan refugees can safely return to their homeland is 'just absurd,' advocates sayNew Foto - Noem's claim that Afghan refugees can safely return to their homeland is 'just absurd,' advocates say

The Trump administration says Afghan refugees can safely return toAfghanistandespite warnings from rights groups and lawmakers that Afghans who worked for the U.S. military face the threat ofpersecution, imprisonment andeven executionby the Taliban regime. The Department of Homeland Securityannounced on Mondayit had stripped legal protections for thousands of Afghans in the U.S., saying that the security and economic situation in Afghanistan no longer justified granting them temporary protected status, or TPS. "We've reviewed the conditions in Afghanistan with our interagency partners, and they do not meet the requirements for a TPS designation," Homeland Security Secretary Kristi Noem said in a statement. "Afghanistan has had an improved security situation, and its stabilizing economy no longer" prevents Afghans from returning to their home country, she said. DHS officials had previously signaled plans to cancel temporary protected status for Afghans but did not formally rescind it until Monday. Lawmakers and rights groups said the Trump administration's decision would put thousands of Afghans' lives at risk and betray partners who had risked their lives to work for the U.S. military during America's 20-year war against the Taliban in Afghanistan. "It's just absurd and divorced from reality to claim that Afghan refugees can safely return to Afghanistan," said Eleanor Acer, senior director for global humanitarian protection for the nonprofit Human Rights First. "Many Afghans would face dire risks of persecution if they are forced back into the hands of the Taliban," Acer said. "Journalists, human rights advocates, religious minorities, women's rights defenders and people who worked with the U.S. military and government are all in danger of Taliban persecution or retaliation if they are forced back to Afghanistan." Kim Staffieri of the Association of Wartime Allies, a nonprofit that helps Afghans who worked for the U.S. government, said it "is unfathomable that DHS can say the economy of Afghanistan has stabilized, that it's much safer now and that Afghans don't need TPS anymore." Apart from reports of the Taliban's human rights abuses, aid groups say Afghanistan is plagued by rising poverty and hunger. According to the World Food Programme, 3.5 million young children are expected tosuffer from malnutritionthis year, the highest level ever recorded in the country. Lawmakers, including some Republicans, said the administration was jeopardizing the lives of those who had stood by the United States. "Afghanistan is not safe," said Democratic Rep. Jason Crow of Colorado, an Army veteran who served in Iraq. "The Taliban continues to crack down on human rights and target Afghans who speak out against them, including those who aided American servicemembers like me during the war. It's cruel and wrong that President Trump is turning his back on those fleeing violence and persecution." Sen. Jeanne Shaheen of New Hampshire, the ranking Democrat on the Senate Foreign Relations Committee, condemned the move as a betrayal and said it contradicted "overwhelming evidence" that Afghans with ties to the U.S. faced persecution and torture by the Taliban. "Deporting our partners to Taliban-controlled Afghanistan is morally indefensible and recklessly endangers lives," she said. Republican Rep. Michael McCaul of Texas, a former chair of the House Foreign Relations Committee, praised President Donald Trump's foreign policy overall but said he was concerned for the safety of Afghan partners. The Taliban "have made their thirst for retribution against those who helped the United States clear," McCaul said. "Until they demonstrate clear behavioral changes, I urge the administration to continue prioritizing the safety of the Afghan men and women who risked their lives to help our troops."

Noem's claim that Afghan refugees can safely return to their homeland is 'just absurd,' advocates say

Noem's claim that Afghan refugees can safely return to their homeland is 'just absurd,' advocates say The Trump administration s...
FDA upheaval pushes some biotech firms to plan early trials out of USNew Foto - FDA upheaval pushes some biotech firms to plan early trials out of US

By Maggie Fick LONDON (Reuters) -Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs watchdog under the Trump administration may delay regulatory reviews, executives, investors, and consultants told Reuters. The U.S. Food and Drug Administration is seen as the global gold standard for drug regulation and companies typically seek American approval first because it provides access to the world's most lucrative drug market. But mass layoffs, leadership exits and the restructuring of the FDA under President Donald Trump are prompting some smaller biotechs to rethink traditional pathways for bringing new medicines to market. Reuters spoke to seven biotech executives, investors, and consultants who said that the staff departures and policy changes at the FDA had prompted some firms to consider launching trials in other international markets - such as the European Union and Australia - and engaging with regulators in those regions earlier in the drug development process. "We know that across our companies, the discussions include whether to go ex-U.S. because of recent FDA uncertainty," said Peter Kolchinsky, managing partner at RA Capital, a major investor in early-stage biotech firms and publicly traded companies with approximately $9 billion in assets under management. The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's restructuring aims to streamline functions such as IT and communications, and reduce conflicts of interest among its staff and advisors. Consultant Matthew Weinberg of ProPharma Group said his firm is fielding more inquiries from biotech companies about preparing filings with the European Medicines Agency and setting up clinical trials - a shift he attributes to growing concerns about FDA stability. "Historically, companies went to the U.S. first. That may be changing," he said. It is unclear if biotech companies' increasing engagement with the EMA marks a real shift or a tactic to pressure the FDA, given the importance of the U.S. market, a source with knowledge of the matter told Reuters. An EMA spokesperson said it has not seen an increase in scientific advice requests or clinical trial applications, noting it would be early for any such shifts to be reflected in submissions. NEW APPROACHES A loss of confidence in the FDA could reshape drug development, reduce U.S. leadership in innovation, and increase costs for the struggling biotech sector, five of those interviewed said. "What's happening has forced all of us to discuss other approaches," said Sabrina Martucci Johnson, CEO of Dare Bioscience, a San Diego-based women's health biotech worth $25 million that received FDA approval in 2021 for its first product. "We are definitely looking at Europe first for certain products where the need is great and the U.S. regulatory path has become more uncertain or slower." Trump on Monday signed an executive order directing drugmakers to lower the prices of their medicines in line with other countries.  Commenting on the executive order, Swiss drugmaker Roche on Tuesday said it is concerned that the order "will undermine the U.S.' position as the world's leading pharmaceutical and healthcare ecosystem." Some biotech executives spoke about early-stage testing on condition of anonymity to avoid drawing attention to their companies or risking retribution for criticising the Trump administration. One biotech CEO said their company plans to seek approval from the EMA to run early-stage clinical trials of its oncology treatment in three European countries - in addition to the trial of the same treatment it launched in the U.S. last October. The expanded European strategy will cost about $1 million in additional filings, consultants, and contract research organisation support - plus several million more to run the trials. "We cannot just hope that things will turn around and that the cuts at the FDA will not have any impact on our business," the executive said. "The irony of this is it goes against the grain of 'America First', because we are offshoring away from the U.S. over to Europe." SLOWER BUT STABLE Another U.S. biotech told Reuters it opted to run two early-stage trials in Australia this month rather than in the U.S. Although some small biotechs had already started to conduct their first in-human trials outside the U.S., particularly in Australia where it is 30% to 40% cheaper, the biotech CEO said that in their firm's case, the decision was driven by FDA staffing cuts and uncertainty. A third biotech CEO said at least two members of the eight-person FDA team reviewing its early-stage trial for an mRNA rare disease therapy have left. They worry this turnover could delay FDA review of trial data. When asked about the impact of shifts at the FDA during earnings calls this month, executives from several big pharma companies including GSK, Merck & Co and Sanofi said they had so far not experienced any changes in their interactions with the regulator. Companies typically file for regulatory approval in the U.S. first to gain access to a market worth approximately $635 billion annually. Even a month or two delay in a regulatory step with the FDA could be existential, said the biotech CEO with the mRNA rare disease therapy. Executives stressed they still intend to run late-stage trials in the U.S. to launch products there. "Europe has been perceived as a little slower, but it has benefited -- and is benefiting now -- from being stable," said Owen Smith, a partner at 4BIO Capital, a London-based venture capital firm that invests in early-stage biotech companies. (Reporting by Maggie Fick; Additional reporting by Emilio Parodi in Milan; Editing by Josephine Mason and Suzanne Goldenberg)

FDA upheaval pushes some biotech firms to plan early trials out of US

FDA upheaval pushes some biotech firms to plan early trials out of US By Maggie Fick LONDON (Reuters) -Some U.S. biotech companies are consi...
Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu saysNew Foto - Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu says

ISTANBUL (Reuters) - Turkish President Tayyip Erdogan met online with U.S. President Donald Trump, Saudi Crown Prince Mohammed bin Salman and Syrian President Ahmed al-Sharaa, state-owned Anadolu news agency reported on Wednesday. Erdogan said during the meeting that Trump's decision to lift sanctions on Syria is of historic importance, Anadolu reported. Trump made the surprise announcement on Tuesday that the U.S. would lift all sanctions on the Islamist-led government in Syria, which had been a key goal for Turkey. (Reporting by Ezgi Erkoyun; Editing by Jonathan Spicer)

Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu says

Turkey's Erdogan met online with Trump, Syrian and Saudi leaders, Anadolu says ISTANBUL (Reuters) - Turkish President Tayyip Erdogan met...

 

TEC POLITICS © 2015 | Distributed By My Blogger Themes | Designed By Templateism.com